Phesgo and Tecentriq Performance and Approvals

Q1 2023: Strong underlying growth in Pharma and Diagnostics % CER +30% +20% Pharma Quarterly sales evolution 2022-2023 Diagnostics Quarterly sales evolution 2022-2023 % CER +30% +24% +20% +8% +10% +7% +9% +9% +4% +10% +10% +3% +6% +4% +9% +0% -2% +3% 0% +0% -4% +2% 0% -10% -9% -6% -10% -20% -28% -20% Q1 Q2 Q3 Q4 Q1 2022 vs. 2021 2023 vs. 2022 -Pharma Pharma excl. Ronapreve Growth rates at CER (Constant Exchange Rates) Roche -30% Q1 Q2 Q3 Q4 Q1 2022 vs. 2021 2023 vs. 2022 --Diagnostics Diagnostics Base business 9

View entire presentation